BEYOND CELIAC

RESEARCH GRANTS: BEYOND CELIAC IS THE LEADING PATIENT-FOCUSED HEALTHCARE NONPROFIT AND FUNDER OF CELIAC DISEASE RESEARCH. THROUGH OUR TRANSLATIONAL RESEARCH PROGRAM... READ MORE ON SCHEDULE O. WE SUPPORT STUDIES, BASED ON OUR COMMUNITY NEEDS, THAT QUICKLY TRANSLATE FROM SCIENTIFIC DISCOVERY INTO CLINICAL USE, WITH THE GOAL OF ADVANCING EFFECTIVE TREATMENTS.AS OF FY24, BEYOND CELIAC HAS AWARDED MORE THAN $3.3 MILLION IN GRANTS, SUPPORTING BOTH EARLY-CAREER AND ESTABLISHED INVESTIGATORS. THE LATEST GRANTS FOCUS ON NON-INVASIVE BIOMARKERS, MICROBIOME RESEARCH, AND IMMUNE TOLERANCE RESTORATION.SELECT AWARDS INCLUDE:1. SHAYNA COBURN, PHD (CHILDREN'S NATIONAL HOSPITAL, DC): INTEGRATING GLUTEN IMMUNOGENIC PEPTIDE TESTING IN A BEHAVIORAL INTERVENTION.2. SHALEV ITZKOVITZ, PHD (WEIZMANN INSTITUTE, ISRAEL): SHED CELL TRANSCRIPTOMICS TO ASSESS CELIAC DISEASE ACTIVITY.3. MICHAEL FITZPATRICK, DPHIL (UNIVERSITY OF OXFORD, UK): NOVEL BIOMARKERS OF MUCOSAL DAMAGE FOR DIAGNOSIS AND MONITORING.4. ROK SEON CHOUNG, MD, PHD (MAYO CLINIC): PREDICTORS OF PROGRESSIVE CELIAC DISEASE PHENOTYPES.5. SONIA GONALVES PEREIRA, PHD (INSTITUTO POLITECNICO DE LEIRIA, PORTUGAL): EXPLORING GLUTEN-MICROBIOTA INTERACTIONS IN DISEASE PROGRESSION.6. KATI JUUTI-UUSITALO, PHD (TAMPERE UNIVERSITY, FINLAND): DEVELOPMENT OF A PATIENT-DERIVED 2D INTESTINAL MODEL.THESE GRANTS ADDRESS CRITICAL BARRIERS IN THE FIELD, INCLUDING A LACK OF FUNDING, UNDERDIAGNOSIS, AND LIMITED PUBLIC AND CLINICAL AWARENESS. THEY ALIGN WITH OUR FOUR STRATEGIC PRIORITIES: TRANSLATIONAL RESEARCH, EVIDENCE GENERATION, CLINICAL TRIAL ACCELERATION, AND OUR VENTURE PHILANTHROPY PROGRAM THROUGH BEYOND CELIAC INVESTMENTS (BCI).

EVIDENCE GENERATION AND CLINICAL TRIALS: THROUGH THE GO BEYOND CELIAC PLATFORM AND OTHER INITIATIVES, BEYOND CELIAC COLLECTS REAL-WORLD DATA FROM INDIVIDUALS WITH CELIAC DISEASE AND NON-CELIAC GLUTEN SENSITIVITY... READ MORE ON SCHEDULE O.THIS EVIDENCE INFORMS RESEARCH PRIORITIES, SUPPORTS FUNDING APPLICATIONS, AND ENSURES PATIENT EXPERIENCES SHAPE THE PATH TOWARD NEW TREATMENTS.WITH UP TO 80% OF CELIAC DISEASE CASES STILL UNDIAGNOSED OR MISDIAGNOSED, GO BEYOND CELIAC PLAYS A VITAL ROLE IN BRIDGING THE GAP BETWEEN LIVED EXPERIENCE AND SCIENTIFIC ADVANCEMENT. THE PLATFORM HAS ENHANCED OUTREACH, INCREASED COMMUNITY PARTICIPATION IN RESEARCH, AND PROMOTED DIVERSITY AND HEALTHCARE EQUITY.BEYOND CELIAC ALSO CONNECTS PATIENTS TO CLINICAL TRIALS, ACCELERATING ENROLLMENT AND FACILITATING DRUG DEVELOPMENT. THESE EFFORTS ARE INSTRUMENTAL IN DE-RISKING THE THERAPEUTIC PIPELINE AND DRAWING INCREASED INTEREST FROM INVESTORS, PHARMACEUTICAL COMPANIES, AND BIOTECH.